Vericel to Report Second-Quarter 2023 Financial Results on August 2, 2023
20 Luglio 2023 - 2:30PM
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies
for the sports medicine and severe burn care markets, today
announced that it will report its second-quarter 2023 financial
results on Wednesday, August 2, 2023. Vericel’s management will
host a conference call and webcast at 8:30 a.m. (ET) to discuss its
financial results and business highlights.
The live webcast can be accessed on the Investor Relations
section of the Vericel website at
http://investors.vcel.com/events-presentations. Please visit the
site at least 15 minutes prior to the scheduled start time in order
to register and download the required audio software, if necessary.
Presentation slides for the conference call will be available on
the webcast and on the Investor Relations section of the Vericel
website.
To participate by telephone, please register here to receive
dial-in details and your personal passcode. A replay of the webcast
will be available on the Vericel website until August 2, 2024.
About Vericel CorporationVericel is a leader in
advanced therapies for sports medicine and severe burn care. The
Company manufactures and markets two cell therapy products and one
specialty biologic product in the United States. MACI® (autologous
cultured chondrocytes on porcine collagen membrane) is an
autologous cellularized scaffold product indicated for the repair
of symptomatic, single or multiple full-thickness cartilage defects
of the knee with or without bone involvement in adults. Epicel®
(cultured epidermal autografts) is a permanent skin replacement for
the treatment of patients with deep dermal or full thickness burns
greater than or equal to 30% of total body surface area. Vericel
also holds an exclusive license for North American rights to
NexoBrid® (anacaulase-bcdb), a biological orphan product containing
proteolytic enzymes, which is indicated for the removal of eschar
in adults with deep partial-thickness and/or full-thickness burns.
For more information, please visit www.vcel.com.
Epicel® and MACI® are registered trademarks of Vericel
Corporation. NexoBrid® is a registered trademark of MediWound Ltd.
and is used under license to Vericel Corporation. © 2023 Vericel
Corporation. All rights reserved.
Investor Contact:Eric Burnsir@vcel.com+1 (734)
418-4411
Media Contact:Julie Downsmedia@vcel.com
Grafico Azioni Vericel (NASDAQ:VCEL)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Vericel (NASDAQ:VCEL)
Storico
Da Mag 2023 a Mag 2024